Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfenex Inc (PFNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,873
  • Shares Outstanding, K 31,460
  • Annual Sales, $ 28,780 K
  • Annual Income, $ -25,680 K
  • 36-Month Beta 2.84
  • Price/Sales 5.52
  • Price/Cash Flow N/A
  • Price/Book 2.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.31
  • Number of Estimates 1
  • High Estimate -0.31
  • Low Estimate -0.31
  • Prior Year 0.23
  • Growth Rate Est. (year over year) -234.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.85 +26.49%
on 11/01/18
5.14 -5.25%
on 11/12/18
+0.51 (+11.70%)
since 10/12/18
3-Month
3.85 +26.49%
on 11/01/18
5.52 -11.78%
on 08/31/18
+0.02 (+0.41%)
since 08/13/18
52-Week
2.07 +135.27%
on 12/18/17
8.42 -42.16%
on 05/15/18
+2.01 (+70.28%)
since 11/13/17

Most Recent Stories

More News
Pfenex (PFNX) Reports Q3 Loss, Misses Revenue Estimates

Pfenex (PFNX) delivered earnings and revenue surprises of -41.67% and -43.33%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

PFNX : 4.87 (-3.56%)
Pfenex Reports Third Quarter Results and Provides Business Update

On track to submit the NDA for PF708 to the FDA in fourth quarter of 2018

PFNX : 4.87 (-3.56%)
Will Pfenex (PFNX) Report Negative Earnings Next Week? What You Should Know

Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PFNX : 4.87 (-3.56%)
Pfenex to Host Conference Call and Webcast Reporting Third Quarter Financial Results on Wednesday, November 7

Pfenex Inc. (NYSE AMERICAN: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology(R) to improve protein therapies for unmet patient...

PFNX : 4.87 (-3.56%)
Pfenex Reports New Employment Inducement Award Under NYSE American Listing Rules

Pfenex Inc. (NYSE American: PFNX) ("Pfenex" or the "Company"), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology(R) to improve protein...

PFNX : 4.87 (-3.56%)
Pfenex to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

Pfenex Inc. (NYSE American: PFNX) announced today that it will be presenting at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York.

PFNX : 4.87 (-3.56%)
Pfenex to Present at the Liolios 7th Annual Gateway Conference

Pfenex Inc. (NYSE American: PFNX) announced today that it will be presenting at the Liolios 7th Annual Gateway Conference in San Francisco, CA.

PFNX : 4.87 (-3.56%)
Pfenex (PFNX) Reports Q2 Loss, Lags Revenue Estimates

Pfenex (PFNX) delivered earnings and revenue surprises of -24.24% and -24.51%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

PFNX : 4.87 (-3.56%)
Liolios 7th Annual Gateway Conference to Showcase 100 Leading Companies at the Four Seasons San Francisco September 5-6, 2018

Corporate Leaders from a Range of Industries to Present to 400+ Institutional Investors and Analysts

BRT : 12.07 (+2.72%)
BBSI : 72.95 (-4.78%)
DSKE : 5.26 (+2.73%)
TGO.TO : 9.72 (-1.12%)
AHT : 5.16 (+2.18%)
VERI : 6.78 (-1.45%)
CDXC : 3.41 (-1.16%)
DUOT : 0.5300 (unch)
IMI : 0.94 (unch)
INUV : 1.27 (+8.55%)
JSDA : 0.3050 (unch)
PRTS : 1.15 (+0.88%)
BMRA : 2.90 (+3.57%)
ESCA : 12.15 (+1.67%)
AEYE : 5.66 (-0.18%)
STKS : 2.97 (-4.19%)
HCI : 53.20 (-2.80%)
AUTO : 2.27 (+5.09%)
PCOM : 12.14 (-2.18%)
INVE : 6.13 (-5.69%)
IMXI : 12.50 (unch)
MVIS : 0.97 (unch)
GMRE : 9.40 (+0.32%)
VTSI : 4.66 (-2.92%)
NTWK : 7.89 (+4.23%)
NBEV : 3.26 (-5.23%)
CLAR : 11.59 (+1.22%)
RSSS : 2.4000 (unch)
TPB : 34.24 (-3.74%)
BLDP : 3.06 (+3.03%)
SBKK : 12.9500 (unch)
TTGT : 15.94 (-3.51%)
ZIXI : 6.37 (-3.92%)
DZSI : 14.34 (+3.69%)
HEAR : 15.01 (-1.77%)
OOMA : 14.76 (-2.57%)
REPR : 1.6000 (-3.03%)
GAIA : 11.85 (-0.42%)
SHSP : 13.27 (+1.76%)
SRT : 6.17 (+1.65%)
GSB : 4.60 (+3.60%)
DMRC : 20.51 (-1.06%)
EVLV : 1.15 (unch)
AJX.TO : 0.85 (unch)
OXBR : 1.06 (+0.95%)
COWN : 15.42 (-1.47%)
SNMX : 1.49 (-0.67%)
EVOA : 0.1500 (unch)
IDSY : 5.84 (-4.34%)
PFNX : 4.87 (-3.56%)
SELF : 4.02 (-0.25%)
MJCO : 7.76 (+4.16%)
UAVS : 0.82 (+1.23%)
CODI : 15.39 (-1.85%)
LXXGF : 0.5836 (-2.57%)
SSTI : 37.18 (+3.11%)
JAKK : 2.42 (-5.47%)
CTG : 4.32 (-1.82%)
CLFD : 12.09 (-8.13%)
AMRK : 12.61 (-1.18%)
HCAC : 10.22 (+0.49%)
PFSW : 6.70 (+0.30%)
Pfenex Announces Positive Top-Line PF708 Study Results in Osteoporosis Patients, On-Track for Submission of New Drug Application in Third Quarter 2018

Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient...

PFNX : 4.87 (-3.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade PFNX with:

Business Summary

Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf'nex Expression Technology (TM) platform...

See More

Key Turning Points

2nd Resistance Point 5.18
1st Resistance Point 5.02
Last Price 4.87
1st Support Level 4.73
2nd Support Level 4.60

See More

52-Week High 8.42
Fibonacci 61.8% 5.99
Fibonacci 50% 5.24
Last Price 4.87
Fibonacci 38.2% 4.50
52-Week Low 2.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar